• Celtaxys Inc., of San Francisco, said it started a Phase I study of CTX-4430, which is designed to block pro-inflammatory enzyme leukotriene A4 hydrolase. The repeat-dose study is aimed at evaluating the safety, tolerability and pharmacokinetics of the drug and will enroll 96 subjects.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter